Topical gene therapy improves ocular complications of dystrophic epidermolysis bullosa

Ophthalmic application of beremagene geperpavec was successful in treating recurrent cicatrizing conjunctivitis in one patient with dystrophic epidermolysis bullosa, according to a study.
“As far as we know this is the first time that topical gene therapy is applied to the eye,” Alfonso L. Sabater, MD, PhD, associate professor of clinical ophthalmology, medical director of the ocular surface program and director of the corneal innovation lab at Bascom Palmer Eye Institute at University of Miami Miller School of Medicine, told Healio.
Beremagene geperpavec (B-VEC, Krystal Biotech), a

Ophthalmic application of beremagene geperpavec was successful in treating recurrent cicatrizing conjunctivitis in one patient with dystrophic epidermolysis bullosa, according to a study.
“As far as we know this is the first time that topical gene therapy is applied to the eye,” Alfonso L. Sabater, MD, PhD, associate professor of clinical ophthalmology, medical director of the ocular surface program and director of the corneal innovation lab at Bascom Palmer Eye Institute at University of Miami Miller School of Medicine, told Healio.
Beremagene geperpavec (B-VEC, Krystal Biotech), a